Quarterly ResultMay 13, 2026, 08:37 AM
Vor Biopharma Q1 Net Loss Widens to $219.6M; Raises $74.9M
AI Summary
Vor Biopharma reported a significant increase in net loss to $219.6 million for Q1 2026, primarily due to a $188.4 million change in the fair value of warrant liabilities. The company successfully completed a private placement in March 2026, raising $74.9 million, contributing to a strong cash position of $491.5 million, which is expected to fund operations for over one year.
Key Highlights
- Net loss for Q1 2026 was $(219.6) million, up from $(32.5) million in Q1 2025.
- Change in fair value of warrant liabilities resulted in an expense of $(188.4) million in Q1 2026.
- Research and development expenses decreased to $17.6 million from $26.7 million year-over-year.
- General and administrative expenses increased to $17.6 million from $6.6 million year-over-year.
- Completed a March 2026 private placement, issuing 5.34 million shares for $74.9 million net proceeds.
- Cash, cash equivalents, and marketable securities totaled $491.5 million as of March 31, 2026.
- Net cash used in operating activities was $(38.2) million for Q1 2026.
- 10.13 million 2025 Warrants were exercised during Q1 2026.